IN THE UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF PENNSYLVANIA

IN RE: GENERIC PHARMACEUTICALS PRICING ANTITRUST LITIGATION	MDL 2724 16-MD-2724
	HON. CYNTHIA M. RUFE
THIS DOCUMENT RELATES TO:	Civil Action No.
Cigna Corp. v. Actavis Holdco U.S., Inc. et al.	20-cv-02711

DEFENDANT ALVOGEN, INC.'S CORPORATE DISCLOSURE STATEMENT

Pursuant to Rule 7.1 of the Federal Rules of Civil Procedure, Alvogen, Inc. states that it is a wholly owned subsidiary of Alvogen Pharma US, Inc. and that no publicly held corporation owns 10% or more stock of either entity.

Respectfully submitted,

AXINN, VELTROP & HARKRIDER LLP

By: /s/ Michael L. Keeley

Michael L. Keeley Rachel J. Adcox 950 F Street, NW Washington, DC 20004 Tel: 202.912.4700

Fax: 202.912.4700

Email: mkeeley@axinn.com

radcox@axinn.com

Edward M. Mathias 90 State House Square Hartford, CT 06013 Tel: 860.275.8112

Fax: 860.275.8112

Email: tmathias@axinn.com

Craig M. Reiser 114 West 47th Street New York, NY 10036 Tel: 212.728.2218

Fax: 212.261.5654

Email: creiser@axinn.com

Counsel for Defendant Alvogen, Inc.

CERTIFICATE OF SERVICE

I hereby certify that on August 26, 2020, I electronically transmitted the foregoing document to the Clerk of Court using the ECF system for filing. A Notice of Electronic Filing was transmitted to all ECF registrants.

/s/ Michael L. Keeley

Michael L. Keeley